

“TDB-DST supports Breakthrough in Stroke Care: Backs India’s First Indigenous Thrombectomy Device by S3V Vascular Technologies”

“TDB-DST Funds India's First Neuro-Intervention Integrated Manufacturing Plant for Stroke Treatment”

Posted On: 30 MAY 2025 5:25PM by PIB Delhi

In a significant boost to India's medtech innovation landscape, the Technology Development Board (TDB), Department of Science and Technology (DST), has extended financial support to M/s S3V Vascular Technologies Limited, Mysuru, for their project titled “Integrated Manufacturing of Mechanical Thrombectomy Kit for Treatment of Acute Ischemic Stroke.” The board has sanctioned assistance to this pioneering initiative aimed at transforming stroke treatment through indigenous innovation.



The project envisions the establishment of a state-of-the-art upstream integrated manufacturing facility at the Medical Devices Park, Oragadam, Sriperumbudur (Chennai), to develop and manufacture advanced mechanical thrombectomy kits—a life-saving intervention for patients suffering from acute ischemic stroke due to large vessel occlusion. Compared to conventional thrombolysis, thrombectomy offers significantly improved outcomes, reducing the risk of long-term paralysis and disability. Thus making a difference between “PARALYSIS and RECOVERY”

S3V Vascular Technologies is set to become the first Indian company to indigenously design and manufacture the complete suite of neuro-intervention devices, including microcatheters, aspiration catheters, guidewires, and stent retriever systems **in an upstream integrated facility**. The company also intends to file patents for critical innovations such as the clot retriever head design, braid-over-coil aspiration catheter structures, and several advanced process technologies.

By replacing expensive imported devices with high-quality, locally manufactured alternatives, this initiative is poised to enhance both affordability and accessibility of stroke care in India. The company aims to integrate these devices into government reimbursement programs such as Ayushman Bharat, thereby unlocking a

domestic market estimated at 2 Billion USD. As part of its outreach, S3V also plans to collaborate with leading hospitals to offer simulator-based training for young interventionalists—especially in Tier-II cities, where the stroke burden is high.

Speaking on the occasion, Sh. Rajesh Kumar Pathak, Secretary, TDB, said “TDB is proud to support S3V’s vision of building India’s first comprehensive neuro-intervention manufacturing ecosystem. This project reflects our continued commitment to making India a global hub for affordable, high-end medical technology—especially in areas of critical public health need like stroke care. The company’s focus on integrating these devices into Ayushman Bharat further aligns with the national goal of inclusive healthcare access.”

Commenting on the support, Dr. N.G. Vijaya Gopal, Managing Director of M/s S3V Vascular Technologies Ltd. Said “With Technology Development Boards’ backing, we are setting a new benchmark in indigenous MedTech manufacturing. Our integrated manufacturing facility will not only reduce dependency on imports of the finished medical devices used in Mechanical Thrombectomy but also reduces India’s dependency on import of the raw materials used in manufacturing of these critical complex lifesaving medical devices. We have initiated the CE and USFDA approval process for these devices to expand our access to cutting-edge stroke care solutions across India, Asia, Latin America, Europe and USA. We’re committed to delivering world-class innovation—designed, engineered, and made entirely in India to the World.”

NKR/PSM

(Release ID: 2132783)